Results for compartmental translation from English to Maltese

This is essentially a compartmental approach.
Dan kollu qiegħed isir fuq bażi frammentat.

2 These pharmacokinetic parameters obtained from the compartmental analysis
2 Dawn il-parametri farmakokinetiċi nkisbu mill-analiżi kompartimentali

non-compartmental analysis (n = 14 / n = 14)
Estimi bbażati fuq analiżi non - kompartmentali (n= 14 / n = 14) 172 1/ m2

Estimates based on non-compartmental analysis (n = 14 / n = 14)
Estimi bbażati fuq analiżi non-kompartmentali (n = 14 / n = 14)

Anti-pegloticase antibodies were associated with an increase in CL and Vc as determined by compartmental analysis.
Antikorpi kontra pegloticase kienu assoċjati ma’ żieda fis-CL u Vc kif iddeterminat permezz ta’ analiżi kompartimentali.

In 40 patients with PNH, a 1-compartmental model was used to estimate pharmacokinetic parameters after multiple doses.
F’40 pazjent b’PNH, intuża mudell ta’ kompartiment wieħed biex jiġu kkalkulati l-parametri farmakokinetiċi wara diversi dożi.

Pharmacokinetic parameters of the non-compartmental analysis after 50 IU/kg dose of ALPROLIX are presented in Table 5
Il-parametri farmakokinetiċi tal-analiżi mhux kompartimentali wara doża ta’ 50 IU doża/kg ta’ ALPROLIX huma ppreżentati f’Tabella 3.

According to the two-compartmental model, the elimination half-life is 18 days for a typical female patient and 20 days for a typical male patient.
Skond il-mudell ta’ żewġ kompartimenti, il-half-life ta’ l- eliminazzjoni hija ta’ 18-il ġurnata għall-pazjenta femminili tipika u ta’ 20 ġurnata għall-pazjent maskili tipiku.

As suggested by compartmental modelling, 9.5 mg/24 h transdermal patches exhibited exposure similar to that provided by an oral dose of 12 mg/day.
Hekk kif indikat minn mudellar tal-kompartimenti, garżi li jipprovdu mediċina li tgħaddi minn ġol- ġilda 9.5 mg/24 siegħa urew esponiment simili għal dak li jinkiseb b’doża orali ta’ 12 mg/jum.

Moreover, the proposal seeks to enhance the existing exchange of information between Member States, which cannot be made by a Member State alone and can be made only in a compartmental way on a bilateral basis by the Member States.
Barra minn hekk, il-proposta tara li ttejjeb l-iskambju eżistenti ta' l-informazzjoni bejn l-Istati Membri, li ma jistax isir minn Stat Membru waħdu u jista' jsir biss b'mod kompartimentali fuq bażi bilaterli mill-Istati Membri.

Moreover, the proposal seeks to enhance the existing exchange of information between Member States, which cannot be made by a Member State alone and can be made only in a compartmental way on a bilateral basis by the Member States.
Barra minn hekk, il-proposta tfittex li ssaħħaħ l-iskambju eżistenti ta' informazzjoni bejn l-Istati Membri, li ma jistax isir minn Stat Membru waħdu u jista' jsir biss b'mod kompartimentali fuq bażi bilaterali mill-Istati Membri.

The very first evaluation of the monitoring of the national implementation of JFS policies appears largely compartmental, and certainly insufficient at this stage, though this observation should not be taken as relieving the Member States of responsibility for the shortcomings that have been observed.
L-ewwel evalwazzjoni tal-monitoraġġ ta’ l-implimentazzjoni nazzjonali ta’ l-oqsma ta’ politika JLS tidher li hi frammentata ħafna, u ċertament mhix biżżejjed f'dan l-istadju, minkejja li din l-osservazzjoni m'għandhiex tkun ikkunsidrata bħala waħda li teħles lill-Istati Membri mir-responsabilità għan-nuqqasijiet li kienu osservati.

The individual half-lives varied from 4.4 to 15.8 hours using a compartmental model and from 4.9 to 14.7 using the non-compartmental method.
Il-half-lives individwali varjaw minn 4.4 sa 15.8 sigħat bl-użu tal-mudell kumpartimentali u minn 4.9 sa 14.7 sigħat bl-użu tal-mudell mhux kumpartimentali.

The individual half-lives varied from 4.4 to 15.8 hours using a compartmental model and from 4.9 to 14.7 using the non-compartmental method.
Iż-żminijiet individwali li jieħdu biex jinżlu bin-nofs varjaw minn 4.4 sa 15.8 sigħat bl-użu tal-mudell kumpartimentali u minn 4.9 sa 14.7 sigħat bl-użu tal-mudell mhux kumpartimentali.

A second population PK analysis with a standard 1 compartmental model was conducted on the multiple dose PK data from 37 aHUS patients receiving the recommended Soliris regimen in studies C08-002A/B and C08-003A/B. In this model, the clearance of Soliris for a typical aHUS patient weighing 70 kg was 0.0139 L/hr and the volume of distribution was 5.6 L. The elimination half-life was 297 h (approximately 12.4 days).
Twettqet it-tieni analiżi għal PK tal-popolazzjoni b’mudell kompartimentali 1 standard fuq dejta PK ta’ dożi multipli minn 37 pazjenti b’aHUS li kienu qed jirċievu l-kors rakkomandat ta’ Soliris fi studji C08-002A/B u C08-003A/B. F’dan mudell, it-tneħħija ta’ Soliris għal pazjent tipiku b’aHUS li jiżen 70 kg kienet ta’ 0.0139 L/siegħa u l-volum tad-distribuzzjoni kien ta’ 5.6 L. Il-half-life tal- eliminazzjoni kienet ta’ 297 siegħa (madwar 12.4 ijiem).

Based on a non- compartmental analysis of data from adults (LAL-CL01/LAL-CL-04), the pharmacokinetics of sebelipase alfa appeared to be nonlinear with a greater than dose-proportional increase in exposure observed between the 1 and 3 mg/kg dosages.
Ibbażat fuq analiżi mhux kompartimentali ta’ dejta minn adulti (LAL-CL01/LAL-CL-04), il- farmakokinetika ta’ sebelipase alfa dehret li mhix lineari b’żieda akbar minn proporzjonali mad-doża fl-esponiment osservat bejn dożaġġi ta’ 1 u 3 mg/kg.

Based on non-compartmental PK analysis, the plasma clearance of paclitaxel with Abraxane was larger (43%) than that following a solvent-based paclitaxel injection and its volume of distribution was also higher (53%).
Ibbażat fuq analiżi PK mhux kompartimentali, it-tneħħija ta’ paclitaxel mill-plażma b’Abraxane kienet ikbar (43%) minn dik b’injezzjoni ta’ paclitaxel ibbażata fuq is-solvent, u l-volum tad-distribuzzjoni tiegħu kien ukoll ogħla (53%).

Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 with dose levels of 10 mg/kg/day and higher (resulting in exposures 0.22 times the human exposure at the maximum recommended human dose based on systemic exposure of ivacaftor and its metabolites; exposures were obtained by non-compartmental analysis [NCA] of plasma concentrations of all subjects in study 5).
Sejbiet ta’ katarretti ġew osservati f’firien ġuvenili li ngħataw doża minn jum 7 sa 35 wara t-twelid b’livelli ta’ doża ta’ 10 mg/kg/jum u ogħla (li rriżultaw f’esponimenti ta’ 0.22 darbiet tal-esponiment fil-bniedem tad-doża massima rakkomandata fil-bniedem ibbażata fuq l-esponiment sistemiku ta’ ivacaftor u l-metaboliti tiegħu; l-esponimenti nkisbu permezz ta’ analiżi mhux kompartimentali non- compartmental analysis [NCA] ta’ konċentrazzjonijiet fil-plażma tal-individwi kollha fi studju 5).

The observed steady-state volume of distribution of sugammadex is approximately 11 to 14 litres in adult patients with normal renal function (based on conventional, non-compartmental pharmacokinetic analysis).
Il-volum tad-distribuzzjoni fl-istat fiss osservat b’sugammadex hu ta’ madwar 11 sa 14-il litru f’pazjenti adulti b’funzjoni renali normali (ibbażat fuq analiżi konvenzjonali farmakokinetika mhux kompartimentali).